Unlocking Insights: Transgenic Solutions for In Vivo Glycobiology Disease Models

At CD BioGlyco, our team of specialists has extensive expertise in the area of Developing Glycobiology Disease Models. We employ a range of Technologies to offer our clients thorough in vivo glycobiology disease model development services. The technologies we possess include gene editing, embryo implantation and cultivation, selective breeding, gene expression, and the transgenic method. The details of our transgenic-based in vivo glycobiology disease model development service are as follows.

• Firstly, our experts engage in communication with you to identify the specific glycobiological disease under study, such as diabetes. Subsequently, they conduct an in-depth examination of the pathophysiology of the disease and the role played by glycosylated biomolecules. Based on the characteristics of the disease and the research objectives, an appropriate animal model such as mice, rats, or zebrafish that accurately replicates the features and progression of the human disease is selected.
• Subsequently, we select appropriate genes or genomes based on the characteristics of the disease under study to mimic the disease progression and design transgenic constructs using transgenic technology.
• Our experts then introduce the designed transgenic constructs into the embryos or stem cells of the target animals by microinjection, electroporation, or virus-mediated methods. The transgenic embryos or stem cells are then transplanted into the recipient mother to grow the transgenic animal, ensuring that the genetic stability and expression pattern of the transgenic animal are as expected.
• Finally, we perform detailed phenotypic analyses of the transgenic animals, including physiology, pathology, and molecular biology, to assess whether the transgenic animals successfully mimic the characteristics of the disease under study.

Publication

Applications

• Transgenic glycobiology disease models have been widely used to study human diseases, particularly to study the consequences of gene overexpression by overexpressing candidate genes associated with disease.
• Transgenic glycobiology disease models have been used to study the mechanistic consequences of gene expression in the wrong cell or at the wrong time point, as well as studies that define embryonic cell fate.
• The model can be used to evaluate the efficacy and safety of new drugs and accelerate the process of developing new drugs. By modelling the physiological and pathological processes of specific diseases, researchers can evaluate the effectiveness of drug candidates.

Advantages

• Models constructed with transgenic technology offer greater control to precisely regulate the expression levels of disease-related genes or alter the structure of glycosylated biomolecules to better mimic the onset and progression of disease.
• Transgenic technology allows researchers to construct many different animal models, including mice, rats, zebrafish, and more, thereby increasing the flexibility and diversity of research and contributing to a more comprehensive understanding of disease.
• Utilizing transgenic technology to build glycobiological models has the potential to expedite the research process and enhance overall research productivity.

CD BioGlyco provides a full range of transgenic-based in vivo glycobiology disease model development services. Our team is committed to delivering dependable and top-notch support for your research in the glycobiology field. If you are interested in further details, please feel free to contact us.